Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Stopped Terminated due to slow accruals.
Conditions
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Mantle Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
- Unresectable Lung Non-Small Cell Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: ROR1 CAR-specific Autologous T-Lymphocytes
Sponsor
Fred Hutchinson Cancer Center
Collaborators